TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A preprint study found that transplanted hearts showed molecular aging patterns associated with their recipients’ age, including signs consistent with rejuvenation in older hearts placed in younger recipients. The findings came from mouse experiments and a small human biopsy analysis; they do not show that a heart’s clinical age or function was reversed, and the report has not been peer-reviewed.
Hearts transplanted from older donors into younger recipients showed molecular signs consistent with a younger biological profile, according to a study posted as a non-peer-reviewed preprint. Researchers also found that younger donor hearts placed in older recipients showed markers associated with aging, but the results do not establish that transplantation reverses clinical aging or improves outcomes.
Teams led by researchers at Brigham and Women’s Hospital and Harvard Medical School examined age-mismatched heart transplants in mice and analyzed archived biopsy samples from human recipients. They used DNA methylation biomarkers, often called epigenetic clocks, alongside gene-expression data to assess how the transplanted heart’s molecular profile related to the recipient’s age.
In the mouse experiments, researchers assessed the transplanted hearts four to six months after surgery. The clocks indicated that older hearts in younger recipients shifted toward younger molecular age estimates, while younger hearts in older recipients shifted in the opposite direction. The researchers reported related age-associated changes in gene expression, including pathways involving inflammation and mitochondrial activity.
The team also analyzed archived biopsies from 11 human transplant recipients, whose donor and recipient ages differed by between 24 years in one direction and 50 years in the other. The estimated biological age of the transplanted hearts was associated with recipient age, broadly resembling the animal findings. The study also examined outcomes among hundreds of recipients one year after transplant and reported associations between recipient age and several functional measures, most consistently exercise capacity. These observations do not show that molecular age shifts caused better or worse outcomes.
Could Age-Mismatched Hearts Expand Supply?
The findings may matter as transplant teams consider how to address the shortage of donor hearts. Donor age is one factor in assessing an organ, and the source report says donors under 45 are generally recommended, while relatively few programs accept hearts from donors over 50. If the heart’s molecular profile can adapt to the recipient’s biological environment, that could eventually inform research into whether some older organs are suitable for transplantation.
That possibility remains a research question, not a basis for changing donor selection. The study measured molecular markers and examined limited clinical data; it did not establish that older hearts become functionally younger, last longer, or produce improved survival. The authors’ findings are best understood as evidence of age-associated molecular adaptation, not proof of clinical rejuvenation.
heart transplant monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Measured Heart Age
Heart transplantation involves a donor organ entering a recipient’s circulation and wider biological environment. The study describes these age-mismatched transplants as heterochronic transplantation. Prior research has raised the possibility that factors circulating in younger organisms can affect aging-related features in other tissues, prompting questions about whether a transplanted organ may also respond to its new host.
In the mouse model used here, the recipient kept its own heart while a second donor heart was connected to blood vessels in the neck. This allowed researchers to study the transplanted organ and compare it with the recipient’s native organs. They reported that the recipient’s heart, liver and blood generally showed little change in biological age after the procedure, suggesting the observed pattern was more apparent in the transplanted heart than across the recipient’s body.
The report was published on bioRxiv as a preprint. As News-Medical’s report cautions, the study had not undergone peer review at publication. Its methods and conclusions therefore require independent scrutiny and further study before they can be treated as established findings.
As an affiliate, we earn on qualifying purchases.
Limits of the Rejuvenation Evidence
The results do not establish how large or lasting the molecular changes are, whether they translate into meaningful changes in heart function, or whether they affect long-term transplant outcomes. The human biopsy analysis included only 11 recipients, and the source report does not provide enough detail to determine how representative those samples were or how other factors may have influenced the estimates.
It is also unclear whether the reported associations between recipient age and one-year functional outcomes reflect changes in the transplanted heart’s biological age, other differences between recipients, or a combination of factors. The study’s preprint status means the findings have not yet been peer-reviewed. No change to clinical practice or donor acceptance criteria is established by this report.
As an affiliate, we earn on qualifying purchases.
Peer Review and Clinical Follow-Up
The next steps are peer review, independent replication and larger studies linking molecular measurements to patient outcomes over time. Researchers would need to determine whether the age-associated signatures persist and whether they correspond to measurable changes in graft performance, complications or survival.
Until such evidence is available, transplant decisions remain matters for transplant teams using established clinical assessments. The preprint offers a potential direction for studying donor-organ age and adaptation, but it does not confirm that older donor hearts can be made younger in a way that benefits recipients.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find about older donor hearts?
In mouse experiments and a small human biopsy analysis, researchers found that molecular age estimates for transplanted hearts were associated with recipient age. Older hearts placed in younger recipients showed markers consistent with a younger profile, but this is not proof of clinical rejuvenation.
Was the study conducted in people?
It included archived heart biopsy samples from 11 human transplant recipients, as well as mouse experiments. The human analysis was small and does not establish that the molecular findings improve patient outcomes.
Does this mean older hearts are now suitable for more transplants?
No. The study does not establish new donor-age rules or show that older hearts perform better after transplantation. Donor-organ decisions continue to depend on clinical assessment by transplant teams.
Has the research been peer-reviewed?
No. The report was available as a bioRxiv preprint, which had not undergone peer review. Its findings should be treated as preliminary rather than conclusive.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
